Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIOTROY THERAPEUTICS operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This matter is assigned to 1 distinct examiner, which points to a streamlined prosecution process. For the company, this means that its current intellectual property focus is directed toward a specific set of claims.
The busiest examiner for BIOTROY THERAPEUTICS is BUNNER, BRIDGET E, who handles 1 busiest examiner pending office action. As there is 1 pending office action in the portfolio, BUNNER, BRIDGET E is the primary contact at the patent office. Practitioners can benefit from this by tailoring their communication and arguments to the specific style of this 1 distinct examiner.
The portfolio's activity is concentrated in 1 distinct art unit. This suggests that the technical scope of the current filing is well-defined within the biotechnology sector. Success in the 1 pending office action will depend on meeting the specific criteria of the 1 distinct art unit. The 1 busiest examiner pending action represents the current milestone for the company's patent strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034568 | USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS | BUNNER, BRIDGET E | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034568 | USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS | BUNNER, BRIDGET E | 55d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034568 | USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS | BUNNER, BRIDGET E | 1647 | §102§112 | Final Rejection | 55d | Pending | Apr 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOTROY THERAPEUTICS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bridget E Bunner has the most, with 1 of BIOTROY THERAPEUTICS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
